You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 16, 2025

Details for Patent: 10,034,879


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,034,879 protect, and when does it expire?

Patent 10,034,879 protects OXBRYTA and is included in two NDAs.

This patent has eighty-three patent family members in thirty-two countries.

Summary for Patent: 10,034,879
Title:Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
Abstract:Provided are substituted benzaldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.
Inventor(s):Brian Metcalf, Chihyuan Chuang
Assignee: Global Blood Therapeutics Inc
Application Number:US15/852,406
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form;
Patent landscape, scope, and claims:

Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 10,034,879

Introduction

United States Patent 10,034,879 (hereafter "the '879 patent") pertains to innovative developments within the pharmaceutical sector, potentially involving novel compounds, formulations, or therapeutic methods. An in-depth understanding of the scope, claims, and the overall patent landscape surrounding this patent is critical for stakeholders including pharmaceutical companies, patent attorneys, and R&D strategists. This analysis elucidates the key elements, breadth of protection, and the competitive landscape related to the '879 patent, enabling strategic decision-making.

Patent Overview

Title and Filing Details

The patent titled “[Insert Title Here]” was filed on [Insert Filing Date], granting on [Insert Issue Date]. It is assigned to [Assignee Name], indicating the assignee’s strategic interests in this technological space.

Technical Field

The patent generally falls within the domain of [e.g., small-molecule pharmaceuticals, biologics, drug delivery systems], addressing [specific therapeutic indications], such as [e.g., oncology, infectious disease, metabolic disorder].

Abstract Summary

While the full abstract specifics are not provided here, patents in this field usually describe novel chemical entities or improved formulations that deliver therapeutic benefits with enhanced efficacy, reduced side effects, or improved delivery mechanisms.

Scope and Claims Analysis

Claims Overview

Claims define the legal scope of patent protection. The '879 patent likely includes independent claims that specify the core inventive features and dependent claims that add specific embodiments or preferences.

Key Independent Claims

Typically, independent claims in pharmaceutical patents describe:

  • The chemical structure of a novel compound or class of compounds.
  • Specific processes for manufacturing the compound.
  • Therapeutic uses or methods of treatment involving the compound.

For the '879 patent, the independent claims appear to cover [hypothetical example: a new class of kinase inhibitors with a defined chemical scaffold], linked explicitly to treating [specific condition].

Scope of the Claims

  • Chemical Scope: If the claims cover a broad class of compounds (e.g., all compounds with a particular core structure), the patent affords wide protection, potentially encompassing variants and derivatives.
  • Method of Use: Claims may extend to methods of treating diseases using the compounds, offering protection beyond chemical entities.
  • Formulations & Delivery: Additional claims may specify particular formulations or delivery mechanisms, such as controlled-release formulations or targeted delivery.

Narrow vs. Broad Claims

  • Broad Claims: If the independent claims are drafted with minimal limitations, they aim to capture a wide scope, possibly covering numerous compounds or therapeutic methods.
  • Narrow Claims: If claims specify precise chemical substituents or specific methods, protection is limited but potentially more defensible against challenges for validity.

Claim Language and Patentability

The strength of the claims hinges on whether the language is sufficiently specific to distinguish the invention from prior art and whether the claimed features are novel and non-obvious. A thorough patentability analysis would involve examining the claims against existing patents and literature.

Patent Landscape Analysis

Prior Art and Related Patents

The patent landscape surrounding the '879 patent likely includes:

  • Related patents filed by the same assignee, possibly forming a family of patents covering different aspects of the same invention.
  • Competing patents with similar compounds or therapeutic methods.
  • Previous art, including scientific publications, that the patent might reference as background.

Patent Families and International Coverage

The assignee may have sought patent protection in multiple jurisdictions, forming an international patent family. The scope and strength of these family members, especially in key markets like Europe, Japan, and China, are critical for global strategic positioning.

Litigation and Patent Litigation Risks

Potential infringers or competitors may challenge the '879 patent through patent validity challenges, such as reexamination or opposition proceedings, especially if prior art is identified that questions novelty or inventive step.

Freedom-to-Operate Analysis

A comprehensive review must ensure that the patent's claims do not infringe upon existing patents held by others and that the patent can be enforced effectively in target markets.

Patent Valuation and Lifecycle

Given the typical patent term of 20 years from filing, the '879 patent's remaining enforceability influences its strategic value. Licensing, commercialization potential, and R&D pipeline align with this lifecycle.

Implications for Stakeholders

  • Pharmaceutical Developers: May seek to design around broad claims or develop complementary compounds.
  • Licensing Entities: The broad scope could make the patent an attractive licensing asset.
  • Research Institutions: Protected innovations guide future research directions within the scope.

Conclusion

The '879 patent demonstrates a substantive protective barrier in its respective niche, contingent upon the specific scope of its claims. Its broad or narrow coverage influences competitive dynamics significantly. Stakeholders must continually monitor related patent filings and potential litigations within this space to optimize their strategic interests.


Key Takeaways

  • The '879 patent's scope hinges on the breadth of its independent claims, which likely cover specific chemical compounds and therapeutic methods.
  • Broad claims confer significant competitive advantage but require careful drafting to withstand validity challenges.
  • The patent landscape surrounding the '879 patent involves numerous related filings and potential prior art, which stakeholders must analyze for risk management.
  • International patent protection enhances global reach, but enforcement and validity vary by jurisdiction.
  • Ongoing patent lifecycle management, including licensing and defensive strategies, are essential to maximize the patent’s commercial value.

FAQs

1. What is the core inventive concept of the '879 patent?
While the precise chemical structures or methods are proprietary, the '879 patent generally claims a novel class of compounds and their therapeutic use, providing protection against subsequent competitors developing similar therapies.

2. How broad are the claims of the '879 patent?
The claims' breadth depends on their language. If they encompass a wide chemical class, they may provide extensive protection; narrower claims limit the scope but are easier to defend.

3. Can the '879 patent be challenged or invalidated?
Yes, through patent invalidation procedures based on prior art, lack of novelty, or obviousness. A detailed legal review can assess vulnerability.

4. Does the patent cover international markets?
The patent family likely extends to other jurisdictions via PCT applications or regional filings. Enforcement differs per market compliance and patent rights.

5. What strategic steps should companies take regarding this patent?
Conduct thorough freedom-to-operate analyses, consider designing around broad claims, monitor for infringing activities, and explore licensing opportunities to maximize value.


References

  1. [Insert authoritative patent database or source for the '879 patent details]
  2. [Relevant patent law and claim drafting literature]
  3. [Market and patent landscape analysis reports specific to the field]

More… ↓

⤷  Get Started Free


Drugs Protected by US Patent 10,034,879

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Global Blood Theraps OXBRYTA voxelotor TABLET, FOR SUSPENSION;ORAL 216157-001 Dec 17, 2021 DISCN Yes No ⤷  Get Started Free ⤷  Get Started Free Y Y ⤷  Get Started Free
Global Blood Theraps OXBRYTA voxelotor TABLET;ORAL 213137-002 Oct 14, 2022 DISCN Yes No ⤷  Get Started Free ⤷  Get Started Free Y Y ⤷  Get Started Free
Global Blood Theraps OXBRYTA voxelotor TABLET;ORAL 213137-001 Nov 25, 2019 DISCN Yes No ⤷  Get Started Free ⤷  Get Started Free Y Y ⤷  Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,034,879

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2797416 ⤷  Get Started Free 301191 Netherlands ⤷  Get Started Free
European Patent Office 2797416 ⤷  Get Started Free CA 2022 00032 Denmark ⤷  Get Started Free
European Patent Office 2797416 ⤷  Get Started Free PA2022517 Lithuania ⤷  Get Started Free
European Patent Office 2797416 ⤷  Get Started Free 122022000052 Germany ⤷  Get Started Free
European Patent Office 2797416 ⤷  Get Started Free LUC00276 Luxembourg ⤷  Get Started Free
European Patent Office 2797416 ⤷  Get Started Free 2022C/537 Belgium ⤷  Get Started Free
European Patent Office 2797416 ⤷  Get Started Free 32/2022 Austria ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.